The chairman of North China Pharmaceuticals, a well-known pharmaceutical company, resigned

On October 29th, North China Pharmaceuticals announced that its board of directors had received a written resignation report from Yang Guo occupied, chairman of the company, on October 26th, 2020.
Yang Guo occupies the board of directors for reasons of his work, and also resigns from the chairman of the company's board of directors strategy (investment decision-making) committee and the nomination and remuneration appraisal committee.
the above-mentioned position, Yang Guo zhan will no longer hold any position in North China Pharmaceuticals.
the announcement, Yang Guocan's resignation report has come into effect, with Vice Chairman Liu Wenfu presiding over the board of directors before North China Pharmaceuticals elects a new chairman.
public information shows that North China Pharmaceuticals, formerly north China Pharmaceutical Factory, began construction in June 1953, completed and put into operation in June 1958, creating a history of large-scale production of antibiotics in China.
China Pharmaceutical Co., Ltd. was restructured in 1992 and listed on the Shanghai Stock Exchange in 1994.
1996, North China Pharmaceutical Factory was officially transformed into a wholly state-owned company - North China Pharmaceutical Group Co., Ltd.
June 2009, with the approval of the Hebei provincial government, Yan Zhong Energy Group carried out a reorganization of China Pharmaceutical Group.
the end of 2018, China Pharmaceutical Group has total assets of 20.6 billion yuan, nearly 15,000 employees, and more than 40 sub-(sub)companies.
According to the 2019 Annual Report, North China Pharmaceutical Products cover more than 700 products such as chemicals, biologics, consumer health care, etc., in the field of treatment including anti-infectant drugs, cardiovascular drugs, kidney disease and immunomodulation drugs, tumor therapy drugs, vitamins and consumer health care products.
Up to now, North China Pharmaceuticals in the field of antibiotics is still in a dominant position, penicillin series, cephalosporin series of products complete, covering the majority of the varieties of raw materials to preparations, including: injection of amoxicillin sodium clavirate potassium, injection of sodium carbapenem, injection of penicillin sodium, amoxicillin capsules, injection of cephalosporinesodium, injection of hydrochloric acid to penicillin and other capsules.
addition, North China Pharmaceuticals also focuses on the development of biologics and cancer therapy drugs, cardiovascular drugs, immunomodulation drugs and other new therapeutic areas with competitive advantages in the industrial chain.
2019, North China Pharmaceuticals' main business in chemical preparations, chemical raw materials, biologics, pharmaceutical and other logistics trade, pharmaceutical intermediates, accounted for 54.31%, 21.41%, 12.66%, 8.11%, 1.86%, respectively.
's revenue grew steadily in the face of the sudden outbreak of new crown pneumonia, domestic chemical preparation manufacturers' revenue and profits, a wide range of decline.
according to data released by the National Bureau of Statistics, in January-June 2020, enterprises mainly producing chemical preparations reported operating income of 381.38 billion yuan, down 8.2% YoY, and realized profits of 51.12 billion yuan, down 15.4% YoY.
this, North China Pharmaceuticals has maintained a good counter-trend rise.
2020 semi-annual report, North China Pharmaceuticals achieved operating income of 5.621 billion yuan, up 5.42% YoY, and total profit of 142 million yuan, up 29.83% YoY.
October 22nd, North China Pharmaceuticals released its third quarter 2020 report, which is still a good performance.
2020, North China Pharmaceuticals achieved revenue of RMB8,638 million, up 7.63 percent year-on-year, and net profit attributable to shareholders of listed companies was RMB128 million, up 39.94 percent year-on-year, according to the announcement.
in its 2019 semi-annual report, North China Pharmaceuticals set its new year revenue target as follows: By 2020, it aims to achieve revenue of 12 billion yuan and total profit of 280 million yuan.
, let's take a look at the performance of North China Pharmaceuticals last year.
's 2019 annual report shows that North China Pharmaceuticals achieved full-year operating income of RMB10,881 million, up 18.09 percent YoY, total profit of RMB237 million, up 19.42 percent YoY, and net profit attributable to shareholders of listed companies of RMB116 million, up 413.86 percent YoY.
Specifically, in 2019, North China Pharmaceuticals further promoted product restructuring, with chemical pharmaceutical revenue reaching 5,909 million yuan, up 9.88 percent year-on-year, and biopharmaceutical revenue reaching 1.378 billion yuan, of which hepatitis B vaccine revenue exceeded 1 billion yuan for the first time, up 57.33 percent year-on-year.
From the above data can be seen, in addition to the main antibiotic products, biological drugs have also begun to become an important part of north China pharmaceutical revenue - North China pharmaceutical analysis, its adjustment of product structure, strengthen chemical agents, biologics, kidney disease and immunomodulation, cardiovascular and other preparation products sales, pharmaceutical and chemical products revenue increased significantly.
the transition to deal with potential risks for some time now, antibiotics have been in a state of strengthening standardized management in the domestic market.
, the antibiotic industry has matured and the growth rate has slowed, according to the Company.
China has also strengthened the clinical use of antimicrobial drugs regulatory management, anti-infective drugs market growth slowed down.
After a period of time, the competitive trend of the global antibiotic market tends to optimize the industrial structure of antibiotic raw materials, improve the comprehensive quality standards and improve the level of environmental protection system, enterprises with core technical capabilities can rely on its cost and quality advantages in the industry to continue to develop.
this, North China Pharmaceuticals has stepped up its research and development investment, which reached 366 million yuan last year, accounting for 3.37% of operating income, maintaining the industry average.
In its annual report, North China Pharmaceuticals said that in order to ensure the company's innovation and sustainable development, will continue to increase product research and development efforts, and actively lay out biopharmaceuticals, cardiovascular, anti-tumor, metabolic, immunomodulation and other fields, through technological innovation to support the company's transformation and development.
North China Pharmaceuticals also pointed out that business development may also face many risks, such as: First, the complex pharmaceutical business environment, the growth rate of the total output value of the pharmaceutical industry slowed down, coupled with the continued strengthening of industry supervision, deepening medical reform policy, enterprises in research and development, environmental protection, capital and other aspects of the cost and risk rise, production and operation is facing pressure and challenges.
Second, the adjustment of the national basic drug catalogue, the optimization of the drug registration review and approval process, consistent evaluation and "4 plus 7" volume procurement and other policies have brought about changes in the business model of pharmaceutical enterprises, the entire pharmaceutical industry opportunities and challenges coexist, in order to adapt to changes in the operating environment, the internal institutional mechanism, structural adjustment, marketing innovation and other reform tasks are difficult.
Third, the reform of the national pharmaceutical industry, the introduction of a number of industrial policies led to the price of pharmaceutical products continued to fall, at the same time, by the continuous improvement of domestic environmental standards, drug quality supervision and other factors, drug production raw materials, energy, power, labor costs and environmental protection management investment has been increasing, further compressing the profit margins of enterprises, increasing the operational risks of enterprises.
Fourth, the pharmaceutical industry's drug research and development has the characteristics of high investment, high risk, long cycle and so on, there are many unpredictable factors in the research and development process, drug marketing will also be affected by the industry, market environment and competition and other factors of uncertainty, so that drug research and development investment and income there is a mismatch risk.
In response to these problems, North China Pharmaceuticals said it will actively respond to industry policy adjustments and market changes, accelerate industrial and product restructuring, innovate institutional mechanisms, innovate product marketing models, upgrade the level of modern management of enterprises, ensure normal production and operation, and effectively reduce operational risks.